Search

Displaying results 2741 - 2750 of 10000 in total
  1. Drug

    Goldenseal

    go.drugbank.com/drugs/DB16594
    Approved

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors
  2. Drug

    Streptococcus pneumoniae type 6a capsular polysaccharide antigen

    go.drugbank.com/drugs/DB16609
    ApprovedInvestigational

    Mixtures: SII PNEUMOSIL Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed) (10-Valent) SUSPENSION FOR INJECTION (SINGLE DOSE - 1 DOSE), SII PNEUMOSIL Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed) (10-Valent) SUSPENSION FOR INJECTION (MULTIDOSE - 5 DOSE)
  3. Drug

    Tyrosinase

    go.drugbank.com/drugs/DB16626
    Investigational

    Tyrosinase is a multi-copper-containing multifunctional metalloenzyme with 4 possible oxidation states. … as melanogenesis).

  4. Drug

    Melphalan flufenamide

    go.drugbank.com/drugs/DB16627
    ApprovedWithdrawn

    Melphalan flufenamide, also known as melflufen or J1, is a prodrug of [melphalan]. … [A230123,L32173] Melphalan flufenamide is more readily uptaken by cells than melphalan, and is cleaved to the active metabolite by aminopeptidases.

  5. Drug

    OPB-111077

    go.drugbank.com/drugs/DB16630
    Investigational

    OPB-111077 is a novel inhibitor of STAT3 and mitochondrial oxidative phosphorylation. It has demonstrated promising anticancer activity in preclinical models.

  6. Drug

    Glyceryl laurate

    go.drugbank.com/drugs/DB16635
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Teclistamab

    go.drugbank.com/drugs/DB16655
    ApprovedInvestigational

    [A253587] On August 24, 2022, the European Commission (EC) granted conditional marketing authorization of teclistamab as first-in-class bispecific antibody for the treatment of multiple myeloma, marking … Teclistamab is an IgG4-PAA bispecific antibody that targets the CD3 receptor expressed on the surface of T cells and B cell maturation antigen (BCMA) expressed on malignant multiple myeloma cells.

    Categories: Bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager
  8. Drug

    Imsidolimab

    go.drugbank.com/drugs/DB16658
    Investigational

    Imsidolimab is under investigation in clinical trial NCT03633396 (A Study to Evaluate the Efficacy and Safety of ANB019 in Subjects With Palmoplantar Pustulosis).

  9. Drug

    Etokimab

    go.drugbank.com/drugs/DB16661
    Investigational

    Etokimab is under investigation in clinical trial NCT03614923 (Etokimab in Adult Patients With Chronic Rhinosinusitis With Nasal Polyps (Crswnp)).

  10. Drug

    Idecabtagene vicleucel

    go.drugbank.com/drugs/DB16665
    ApprovedInvestigational

    Multiple myeloma is a cancer where plasma cells rapidly divide out of control. … [A232558,A232563,L32858] These therapies involve extracting and genetically manipulating T-cells from a patient to express a CAR for a tumor specific antigen.

    Categories: Receptors, Antigen, T-CellSynonyms: Anti-BCMA CAR T cell